Research funding intelligence
See who funds the science around your target.
Atlas gathers grants from NIH RePORTER and EU CORDIS, and the funders acknowledged in the papers of your project. You see which labs are funded, by whom, and on what, next to your literature and trials.
- funding records linked to the project
- 171
- sources, public registries and papers
- 4
- EU projects with budget and dates
- 25
- drug makers among the funders most cited in papers
- 4
Step 1 of 3
Grants from the registries, funders from the papers
Registries give amounts, dates and institutions. Paper acknowledgments show who paid for the work you are reading, including companies.
Step 2 of 3
Spot the funded labs working on your exact question
Grants are matched to the project, so a resistance-focused proof-of-concept grant surfaces next to the trials it could inform.
Overcoming adaptive KRAS inhibitor resistance with ligand-directed KRAS G12V-panTEAD chimeras
NIH · National Cancer Institute · Enfuego Therapeutics · 2026–2027 · $311,734
PREDICT: longitudinal models of RAS direct inhibition to combat tumor resistance
ERC Proof of Concept · Università degli Studi di Torino · 2025–2026 · €150,000
Step 3 of 3
See who pays for the papers you cite
Public agencies and drug makers appear side by side in the acknowledgments. Useful for partnering, and for reading a paper with its funding in mind.
- Amgenindustry7
- National Natural Science Foundation of China6
- Japan Society for the Promotion of Science4
- National Research Foundation of Korea3
- Academy of Finland3
- AstraZenecaindustry3
- Bristol-Myers Squibbindustry3
- Novartisindustry3
Example output
Largest EU lung cancer projects linked to this landscape
From EU CORDIS, with budget, coordinator and dates.
| Project | Programme | Coordinator | EU budget | Period |
|---|---|---|---|---|
| SPACETIMESpatial analysis of cancer evolution in the tumour immune microenvironment | Horizon Europe · Health | Amsterdam UMC | €11.8M | 2024–2029 |
| I3LUNGIntegrative science and an intelligent data platform for individualized lung cancer care | Horizon Europe · Health | Istituto Nazionale dei Tumori, Milan | €10.0M | 2022–2027 |
| PREDICTLongitudinal models of RAS direct inhibition | ERC Proof of Concept | Università degli Studi di Torino | €0.15M | 2025–2026 |
Map the funding around your own target
We set up a project on your disease and target with you, and walk through who funds what.
Request a demoFunding sync of the example project (KRAS G12C · non-small cell lung cancer) on 11 Oct 2026, from NIH RePORTER, EU CORDIS, Europe PMC and Crossref funder metadata.